Equities research analysts expect that Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) will announce earnings of ($0.68) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Tonix Pharmaceuticals Holding Corp.’s earnings, with the lowest EPS estimate coming in at ($0.71) and the highest estimate coming in at ($0.64). Tonix Pharmaceuticals Holding Corp. posted earnings per share of ($2.60) during the same quarter last year, which indicates a positive year over year growth rate of 73.8%. The firm is expected to issue its next quarterly earnings report on Thursday, November 9th.
According to Zacks, analysts expect that Tonix Pharmaceuticals Holding Corp. will report full year earnings of ($2.96) per share for the current fiscal year, with EPS estimates ranging from ($3.10) to ($2.81). For the next fiscal year, analysts expect that the business will post earnings of ($2.31) per share, with EPS estimates ranging from ($2.79) to ($1.60). Zacks’ EPS averages are a mean average based on a survey of analysts that that provide coverage for Tonix Pharmaceuticals Holding Corp..
Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) last announced its quarterly earnings results on Monday, August 14th. The company reported ($0.65) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.78) by $0.13.
Several equities analysts have recently issued reports on the stock. Roth Capital raised shares of Tonix Pharmaceuticals Holding Corp. from a “neutral” rating to a “buy” rating and set a $6.00 price objective on the stock in a research note on Friday, August 18th. They noted that the move was a valuation call. Dawson James reiterated a “buy” rating and issued a $9.00 target price on shares of Tonix Pharmaceuticals Holding Corp. in a report on Wednesday, August 23rd. Aegis started coverage on shares of Tonix Pharmaceuticals Holding Corp. in a report on Monday, June 26th. They issued a “buy” rating and a $10.00 target price for the company. Drexel Hamilton started coverage on shares of Tonix Pharmaceuticals Holding Corp. in a report on Tuesday, August 22nd. They issued a “buy” rating for the company. Finally, ValuEngine upgraded shares of Tonix Pharmaceuticals Holding Corp. from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. Tonix Pharmaceuticals Holding Corp. currently has a consensus rating of “Buy” and a consensus target price of $8.33.
Shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ TNXP) opened at 4.25 on Wednesday. The stock’s market cap is $31.91 million. The firm has a 50 day moving average of $3.63 and a 200 day moving average of $3.68. Tonix Pharmaceuticals Holding Corp. has a one year low of $0.33 and a one year high of $9.40.
COPYRIGHT VIOLATION NOTICE: This report was posted by Stock Observer and is the sole property of of Stock Observer. If you are accessing this report on another website, it was illegally stolen and republished in violation of international copyright laws. The correct version of this report can be read at https://www.thestockobserver.com/2017/09/13/brokerages-anticipate-tonix-pharmaceuticals-holding-corp-tnxp-will-post-earnings-of-0-68-per-share.html.
In other news, CEO Seth Lederman bought 20,000 shares of the firm’s stock in a transaction on Thursday, August 17th. The stock was bought at an average cost of $3.00 per share, for a total transaction of $60,000.00. Following the completion of the acquisition, the chief executive officer now directly owns 11,166 shares in the company, valued at approximately $33,498. The purchase was disclosed in a document filed with the SEC, which is available at this link. Also, Director Ernest Mario sold 6,105 shares of the firm’s stock in a transaction dated Friday, June 30th. The stock was sold at an average price of $4.28, for a total transaction of $26,129.40. Following the completion of the transaction, the director now owns 63,073 shares of the company’s stock, valued at $269,952.44. The disclosure for this sale can be found here. Over the last quarter, insiders acquired 50,000 shares of company stock valued at $188,050. Corporate insiders own 4.00% of the company’s stock.
Several institutional investors and hedge funds have recently made changes to their positions in the business. Citadel Advisors LLC acquired a new position in shares of Tonix Pharmaceuticals Holding Corp. in the first quarter worth about $119,000. Dialectic Capital Management LP acquired a new position in shares of Tonix Pharmaceuticals Holding Corp. in the first quarter worth about $187,000. Vanguard Group Inc. boosted its holdings in shares of Tonix Pharmaceuticals Holding Corp. by 28.8% in the second quarter. Vanguard Group Inc. now owns 184,377 shares of the company’s stock worth $799,000 after buying an additional 41,264 shares during the period. Finally, B. Riley Financial Inc. acquired a new position in shares of Tonix Pharmaceuticals Holding Corp. in the second quarter worth about $1,637,000. Institutional investors own 28.80% of the company’s stock.
About Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp., a clinical-stage pharmaceutical company, engages in developing pharmaceutical products for central nervous system disorders. The companys lead program focuses on post-traumatic stress disorder (PTSD) that is characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and economic burden.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tonix Pharmaceuticals Holding Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals Holding Corp. and related companies with MarketBeat.com's FREE daily email newsletter.